< Back to latest news & events

Blog Posts

AI-Powered Personalised Medicine

September 2023

The integration of artificial intelligence (AI) into healthcare has ushered in a new era of personalised medicine, promising more effective and tailored treatments for patients. Traditional medical approaches often adopt a one-size-fits-all model, but AI-powered personalised medicine is changing the game by harnessing the power of data, machine learning (ML), and advanced analytics to create individualised healthcare plans.  

Personalised medicine or healthcare, also known as precision medicine, is an approach to healthcare that customises medical decisions, practices, and products to the individual patient. The goal is to provide treatments that are more effective, minimise side effects, and optimise outcomes based on each patient’s unique genetic makeup, medical history, and lifestyle. 

AI plays a pivotal role in personalised medicine by processing vast amounts of patient data, identifying patterns, and generating insights that aid in diagnosis, treatment selection, and prognosis. Here’s a few examples of how AI is revolutionising personalised medicine: 

Data Analysis and Integration: AI algorithms excel at processing and integrating diverse data types, including genetic information, medical records, imaging, and wearable device data. This comprehensive view of a patient’s health allows for a more accurate and holistic assessment. 

Genomic Medicine: AI is instrumental in analysing an individual’s genetic makeup. By identifying specific genetic markers and mutations, AI can predict disease susceptibility, select targeted therapies, and even predict the likelihood of treatment success. 

Drug Discovery and Development: AI accelerates drug discovery by sifting through vast chemical libraries, predicting potential drug candidates, and assessing their safety and efficacy. This approach streamlines the development process, reducing costs and timelines. 

Treatment Personalisation: AI can analyse patient data to identify the most suitable treatment options, including drug dosages and therapy regimens. This ensures that treatments are tailored to an individual’s unique needs, improving both effectiveness and patient compliance. 

Disease Prediction and Prevention: AI models can predict disease onset by analysing patient data and recognising early warning signs. This allows for proactive interventions, lifestyle adjustments, and preventive measures. 

Real-Time Monitoring: Wearable devices and sensors equipped with AI algorithms enable continuous health monitoring. These devices can detect abnormalities and alert healthcare providers and patients, enabling timely intervention. 

These are examples of AI in personalised medicine. However, AI is also progressing innovation in healthcare more broadly too, as demonstrated by the Food and Drug Administration (FDA) in the US which has put together a list of AI/ML medical algorithms that are cleared for the market. So far, there are over 500 that have been cleared and the majority of these relate to medical imaging, for example, in diagnostics [1].  

The Medicines and Healthcare Products Regulatory Agency (MHRA) has not published a similar list; however the UK government recognises the importance of AI’s role in future healthcare and announced in March 2023 that they are funding nine of the most promising AI healthcare technologies to accelerate research [2]. Similarly, in August 2023, the UK Government announced 22 projects that will receive funding to explore how to develop and use AI in healthcare. One of these projects (University of Oxford) relates to personalised healthcare where AI is used for clinical risk prediction to determine the likelihood of future health problems based on an individual’s existing conditions.  The UK Government have also appointed two leading experts to take the lead on UK hosting the first major international summit on safe use of AI, Autumn 2023. [3]  

The progression of medical technology in general is also reflected in the number of patent filings where medical technology was one of the main drivers of growth in patent filings at the EPO in 2022. Looking at the number of AI patent applications published by the EPO, this number has significantly increase over the last few years and in 2022 over 10 000 AI patent applications were published.  

AI-powered personalised medicine represents a shift in healthcare, moving away from one-size-fits-all approaches, towards tailored treatments and interventions. By harnessing the capabilities of AI to analyse vast datasets and extract meaningful insights, healthcare providers can offer more precise diagnoses, treatment plans, and preventive strategies. As research and technology continue to advance, AI-powered personalised medicine will continue to reshape the way we understand and approach healthcare. 

 

This article was prepared by HGF Patent Director Dr Sofie McPherson

 

[1]. https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices#resources 

[2]. https://www.gov.uk/government/news/thousands-of-patients-to-benefit-from-quicker-diagnosis-more-accurate-tests-from-ground-breaking-ai-research 

[3] https://www.gov.uk/government/news/experts-to-lead-ai-safety-summit-preparations-as-new-funding-announced-to-modernise-healthcare 

 

Latest updates

A New Era for AI Patents in the UK: Supreme Court Aligns with the EPO

The UK Supreme Court has handed down its long-awaited judgment in Emotional Perception AI Limited (EPAI) vs Comptroller General of Patents, a decision which serves to significantly change the way …

Read article
Event - 23rd - 25th March 2026

HGF are Gold Sponsors of IPBC Europe 2026

HGF are proud sponsors of IPBC Europe 2026, taking place from 23-25 March 2026 at the Pullman Paris Montparnasse. Bringing together patent pioneers, in-house leaders and private practice specialists, IPBC …

Event details
Event - 8th - 11th February 2026

AUTM Meeting 2026

We are attending the AUTM Annual Meeting from 8–11 February, a flagship event bringing together technology transfer professionals from across the globe. AUTM connects innovators, universities, and industry leaders to …

Event details

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details